BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

13 articles for WJ Fairbrother

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.EBI
Abbvie
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.EBI
Genentech
Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.EBI
Genentech
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).EBI
Genentech
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.EBI
The Walter and Eliza Hall Institute of Medical Research
Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.EBI
Genentech
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.EBI
Abbvie
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability.EBI
Genentech
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XEBI
Abbvie
Tricyclic compounds as anticancer agentsBDB
Bristol-Myers Squibb
Pyridine compounds used as PI3 kinase inhibitorsBDB
Teligene
Synthesis and target identification of hymenialdisine analogs.BDB
Genomics Institute of The Novartis Research Foundation
Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.BDB
Parke-Davis Pharmaceutical Research